Feedback / Questions
hydroxyureamethylacylfulvene (STAR-001) - Lantern Pharma
https://www.businesswire.com/news/home/20251203887903/en/Lantern-Pharma-Reports-Additional-Positive-LP-184-Phase-1a-Results-Showing-Durable-Disease-Control-in-Heavily-Pre-Treated-Advanced-Cancer-Patients-as-Company-Advances-Precision-Oncology-Program-into-Multiple-Biomarker-Guided-Phase-1b2-Trials
Dec 4, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next